9 196

Cited 0 times in

Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen.

Authors
Park, HS; Nahm, DH; Kim, HY; Suh, YJ; Cho, JW; Kim, SS; Lee, SK; Jung, KS
Citation
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 86(4):444-448, 2001
Journal Title
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN
1081-12061534-4436
Abstract
BACKGROUND AND OBJECTIVE: Hop Japanese (Hop J) pollen has been reported as one of the major causative pollen allergens in the autumn season. There have been no published data regarding the clinical and immunologic effects of Hop J pollen immunotherapy in sensitized patients. In this study, we evaluated clinical and immunologic effects of Hop J immunotherapy.



PATIENTS AND METHODS: Pollens were collected in our area, and "Depo-Hop J" was prepared in the laboratory of Allergopharma (Reinbek, Germany). Fifteen asthmatic patients who had Hop J immunotherapy for > 1 year were enrolled. Their clinical parameters, such as asthma symptom scores, were monitored. Skin reactivity to Hop J and degree of airway hyperresponsiveness to methacholine were measured before and 1 year after the immunotherapy. Sera were collected before the immunotherapy, at the end of initial therapy, and 1 year after the therapy. Serum total IgE levels were compared by radioimmunoassay. Serum-specific IgE, IgG1, and IgG4 levels to Hop J were compared by ELISA. To evaluate the changes of cellular mechanisms, soluble CD30 (sCD30), soluble interleukin (IL)-2 receptor (sIL-2R), soluble CD23 (sCD23), and IL-10 levels were measured by ELISA.



RESULTS: Specific IgG1 and IgG4 levels began to increase at the end of the initial therapy (P < 0.05) with significant decreases in symptom scores (P < 0.05), whereas total and specific IgE levels showed variable responses during the immunotherapy with no statistical significance (P > 0.05). Serum sIL-2R and sCD30 levels decreased significantly (P < 0.05) 1 year after immunotherapy. No significant changes were noted in sCD23, IL-10, skin reactivity to Hop J, or airway responsiveness to methacholine (P > 0.05).



CONCLUSIONS: We are certain that Hop J allergen immunotherapy, if carried out properly according to suitable indications, can favorably influence asthma. Thus, an increase in specific IgG4 and IgG1 antibodies and reduction of a possible Th2 lymphocyte marker (sCD30) may be associated with symptomatic improvements.
MeSH terms
AdolescentAdultAllergens/diagnostic useAllergens/therapeutic useAntigens, CD30/bloodBronchial Hyperreactivity/diagnosisDesensitization, Immunologic*FemaleHumansImmunoglobulin E/bloodImmunoglobulin G/bloodInterleukin-10/bloodMaleMethacholine Chloride/diagnostic useMiddle AgedPollen/immunology*Receptors, IgE/bloodReceptors, Interleukin-2/bloodRhinitis, Allergic, Seasonal/drug therapy*Rhinitis, Allergic, Seasonal/immunology*Skin Tests
DOI
10.1016/S1081-1206(10)62493-3
PMID
11345290
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Allergy
AJOU Authors
박, 해심남, 동호서, 유진
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse